“…(3) By the FDA-approval level achieved, if any, in the works presented by Wang et al [ 7 ], Leirós-Rodríguez et al [ 8 ], Rucco et al [ 9 ], Stavropoulos et al [ 10 ], and Tun et al [ 11 ], no type of FDA approval was proposed. Likewise, others works have identified the monitoring of patients with chronic degenerative diseases [ 12 , 13 , 14 , 15 , 16 ], wearables for promoting physical activities (the deficiency of physical activity has been determined as a crucial influence in developing chronic diseases) [ 17 , 18 , 19 ], movement disorders (e.g., Parkinson’s disease, freezing of gait) [ 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 ], development of sensors and wearable technologies [ 32 , 33 , 34 , 35 , 36 ], wearable device use evaluations [ 8 , 10 , 37 , 38 , 39 , 40 , 41 , 42 ], measurement of biomedical variables and parameters [ 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 ], and other works have reviewed reviews related to wearables appli...…”